The FDA drug approvals database lists a supplement, dated 24 September 2026, to Baxter's application for daptomycin premixed in 0.9% sodium chloride. The record names the product and the applicant but does not say what the supplement changed.
Supplements are routine and most concern labelling, manufacturing or packaging. Nothing in the record suggests a safety finding or a new indication. Premixed daptomycin is a US product; whether an equivalent ready-to-use form is available in India is not stated.
- The supplement is to Baxter's application for daptomycin premixed in 0.9% sodium chloride.
- It was recorded on 24 September 2026.
- Supplements can cover labelling, manufacturing or packaging changes.
- Daptomycin remains a standard option for MRSA bacteraemia; dose by actual body weight and monitor creatine kinase weekly.
Why it matters
Ready-to-use premixed antibiotics reduce preparation errors on busy wards, so label changes to them are worth noticing.
Don't overread it
A licence supplement is not a new indication, and the FDA record does not describe the change.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free